1. Accueil
  2. Publications

Publications

Résultats trouvés 7
Auteur Titre [ Type(Desc)] Année
Filtres: Mot-clé is Aged and Auteur is Boulahssass, Rabia  [Réinitialiser les filtres]
Journal Article
Hannoun-Lévi J-M, Montagne L, Sumodhee S, Schiappa R, Boulahssass R, Gautier M, Gal J, Chand M-E.  2021.  APBI Versus Ultra-APBI in the Elderly With Low-Risk Breast Cancer: A Comparative Analysis of Oncological Outcome and Late Toxicity.. Int J Radiat Oncol Biol Phys. 111(1):56-67.
Couderc A-L, Boulahssass R, Nouguerède E, Gobin N, GuÉrin O, Villani P, Barlesi F, Paillaud E.  2019.  Functional status in a geriatric oncology setting: A review.. J Geriatr Oncol. 10(6):884-894.
Boulahssass R, Gonfrier S, Ferrero J-M, Sanchez M, Mari V, Moranne O, Rambaud C, Auben F, Levi J-MHannoun, Bereder J-M et al..  2018.  Predicting early death in older adults with cancer.. Eur J Cancer. 100:65-74.
Poisson J, Martinez-Tapia C, Heitz D, Geiss R, Albrand G, Falandry C, Gisselbrecht M, Couderc A-L, Boulahssass R, Liuu E et al..  2021.  Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer).. J Cachexia Sarcopenia Muscle. 12(6):1477-1488.
Boulahssass R, Chand M-E, Gal J, Dittlot C, Schiappa R, Rambaud C, Gonfrier S, GuÉrin O, Hannoun-Levi JMichel.  2021.  Quality of life and Comprehensive Geriatric Assessment (CGA) in older adults receiving Accelerated Partial Breast Irradiation (APBI) using a single fraction of Multi-Catheter Interstitial High-Dose Rate Brachytherapy (MIB). The SiFEBI phase I/II trial.. J Geriatr Oncol. 12(7):1085-1091.
Galvin A, Bertrand N, Boulahssass R, de Decker L, Dorval É, Clairaz B, Castaignède M, Mourey L, Baldini C, Bauvin E et al..  2022.  [Rethinking the management of elderly cancer patients : Proposals from the Age Cancer Priorities French Group].. Bull Cancer. 109(6):714-721.
Boisteau E, François E, Aparicio T, Le Malicot K, Boulahssass R, Lecomte T, Laurent-Puig P, Guiu B, Paillaud E, Galais M-P et al..  2022.  SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.. Dig Liver Dis. 54(6):747-754.